Article Text

PDF
Update on toll-like receptor-directed therapies for human disease
  1. Kevin Tse,
  2. Anthony A Horner
  1. Departments of Medicine and Pediatrics and The Sam and Rose Stein Institute for Aging, University of California, San Diego, California, USA
  1. Anthony A Horner, University of California, San Diego, 9500 Gilman Drive, Mail code 0663, La Jolla, CA 92093-0663, USA; ahorner{at}ucsd.edu

Abstract

Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.

Statistics from Altmetric.com

Footnotes

  • Funding: This work was supported by grant AI61772 from the National Institutes of Health.

  • Competing interests: None declared.

  • Abbreviations:
    CTL
    cytotoxic T lymphocyte
    MPL
    monophosphoryl lipid
    ODN
    oligodeoxynucleotide
    PAMPs
    pathogen-associated molecular patterns
    PRRs
    pattern recognition receptors
    SLE
    systemic lupus erythematosus
    TLRs
    toll-like receptors

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.